Advances in hidradenitis suppurativa
Transcript: Real-world data and emerging medications
Dr Philippe Guillem
Interview recorded Feb 2024, EHSF 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
An important point during the medical treatment session is the confirmation that well-known biologics can be used. Two of them that already received an agreement are adalimumab and bimekizumab and real-world study have been presenting from Spain, from Ireland, for example, and confirmed the interest in a real-world use. There are also new studies about new classes of treatment such as the JAK-1 inhibitors and probably this kind of drugs will be used in the future. There are only phase two studies that have been printed, so there are no agreement about this kind of treatment.
Phase three study will begin and it will be interesting to see that. About phase three studies, the inhibitor of interleukin-17A and F, bimekizumab also confirmed the results as regards the problems from the patients, what, notably, according to the control of pain or quality of life, there is an improvement with this kind of treatment, we are still waiting for the agreement for this molecule.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
This content has been developed independently of the sponsor, UCB Biopharma SRL, which has had no editorial input into the content. EPG Health received funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.